LAS VEGAS, NV--(Marketwired - Feb 18, 2015) - Cell MedX Corp. (OTC PINK: CMXC) (OTCQB: CMXC), (the "Company") is pleased to announce that the Company has received an approval from the OTC Markets to upgrade to the OTCQB venture stage marketplace. The Company will transition from the OTC Pink open marketplace to the OTCQB on February 18, 2015.

About Cell MedX Corp.:

Cell MedX Corp. is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. Through its wholly owned subsidiary, Avyonce Cosmedics Inc., Cell MedX Corp. is also engaged in the resale and marketing of spa technology and equipment.

On behalf of the Board of Directors of Cell MedX Corp.

Frank McEnulty
Chief Executive Officer and President.

For further information about Cell MedX Corp. please visit the Company's website at Or phone us at 310-230-2300 x-1

Contact Information:

Cell MedX Corp
310-230-2300 x-1